24 October 2019
Visiongain has launched a new pharma report Global Protein Expression Market Forecast to 2029: Cell-free Expression System, Prokaryotic/Bacterial Expression System, Yeast Cell Expression Systems, Algal-based Expression Systems, Insect Cell Expression Systems, Mammalian Cell Expression Systems, Reagents, Expression Vectors, Competent Cells, Instruments, Services, Therapeutic Applications, Industrial Application, Research Application, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs).
The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.
The lead analyst of the report commented "Recombinant proteins will continue to be essential reagents for drug discovery projects in the future and that technological developments will emerge to match changes in demand or to keep in step with advances in other application areas. Another great opportunity for future growth in the protein expression market is provided by emerging countries, especially China and India. Their markets are growing at a faster rate than that of the developed Western markets.
The demand for expertise in recombinant protein expression development is another opportunity for the market, and this will allow smaller niche companies to compete with the large multinational CROs, resulting in more companies entering the market and more products and services being offered."
Leading companies featured in the report include Agilent Technologies, Bio-Rad Technologies, EMD Milipore, New England Biolabs, Inc., Oxford Expression Technologies, Ltd., Promega Corporation, Qiagen NV, Takara Bio, Inc., Thermo Fisher Scientific, Inc. and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.
04 December 2019
Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.
04 December 2019
The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
04 December 2019
Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.